---
title: "Shanghai Innostar Biotechnology Full Year 2024 Earnings: EPS: CN¥1.26 (vs CN¥1.84 in FY 2023)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/230408270.md"
description: "Shanghai Innostar Biotechnology reported its Full Year 2024 earnings, revealing an EPS of CN¥1.26, down from CN¥1.84 in FY 2023. Revenue increased by 9.9% to CN¥1.14 billion, but net income fell by 24% to CN¥147.8 million, resulting in a profit margin decrease from 19% to 13% due to higher expenses. The company's shares have declined by 7.0% over the past week, and there is one warning sign identified in their risk analysis."
datetime: "2025-03-04T02:11:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/230408270.md)
  - [en](https://longbridge.com/en/news/230408270.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/230408270.md)
---

# Shanghai Innostar Biotechnology Full Year 2024 Earnings: EPS: CN¥1.26 (vs CN¥1.84 in FY 2023)

## Shanghai Innostar Biotechnology (SHSE:688710) Full Year 2024 Results

### Key Financial Results

-   Revenue: CN¥1.14b (up 9.9% from FY 2023).
-   Net income: CN¥147.8m (down 24% from FY 2023).
-   Profit margin: 13% (down from 19% in FY 2023). The decrease in margin was driven by higher expenses.
-   EPS: CN¥1.26 (down from CN¥1.84 in FY 2023).

SHSE:688710 Earnings and Revenue History March 4th 2025

_All figures shown in the chart above are for the trailing 12 month (TTM) period_

Shanghai Innostar Biotechnology shares are down 7.0% from a week ago.

### Risk Analysis

What about risks? Every company has them, and we've spotted **1 warning sign for Shanghai Innostar Biotechnology** you should know about.

### Related Stocks

- [688710.CN](https://longbridge.com/en/quote/688710.CN.md)

## Related News & Research

- [Nippo lifts profits and cash, delivers hefty special dividend ahead of earnings plateau](https://longbridge.com/en/news/286837429.md)
- [Interested In Arabian Internet and Communication Services' (TADAWUL:7202) Upcoming ر.س8.00 Dividend? You Have Three Days Left](https://longbridge.com/en/news/286635446.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [A Look At UroGen Pharma (URGN) Valuation After New UGN-103 And ZUSDURI Bladder Cancer Data](https://longbridge.com/en/news/286722721.md)
- [15:43 ETUnleashed Brands Foundation Donates $200,000 to Blood Cancer United in Support of Pediatric Blood Cancer Patients & Their Families](https://longbridge.com/en/news/286811594.md)